# PDUFA dates August 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-08

> 539 FDA catalysts are dated in August 2026, including 14 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in August 2026?

PDUFA dates in August 2026: Opdivo® (nivolumab, REPL) on August 2, 2026; Replimune Group, Inc. (REPL) on August 2, 2026; intismeran (MRNA) on August 5, 2026; deramiocel (CAPR) on August 10, 2026; BRISTOL MYERS SQUIBB CO (BMY) on August 17, 2026; cisplatin (MRK) on August 17, 2026; and 8 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-08)

Source: SEC Form 10-K, accession 0001628280-26-045886, https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm (retrieved 2026-11-12). Last confirmed 2026-06-29. Cite: https://sec-api.dev/fda-calendar/2026-08#answer

## PDUFA dates in August 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| August 2, 2026 | Replimune Group, Inc. | REPL | Opdivo® (nivolumab) |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm) |
| August 2, 2026 | Replimune Group, Inc. | REPL |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926078009/tm2619037d1_ex99-1.htm) |
| August 5, 2026 | Moderna, Inc. | MRNA | intismeran |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm) |
| August 10, 2026 | CAPRICOR THERAPEUTICS, INC. | CAPR | deramiocel |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813xex99d1.htm) |
| August 17, 2026 | BRISTOL MYERS SQUIBB CO | BMY |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000008/a2026q1ex991.htm) |
| August 17, 2026 | Merck & Co., Inc. | MRK | cisplatin |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm) |
| August 17, 2026 | PFIZER INC | PFE | cisplatin |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm) |
| August 22, 2026 | CAPRICOR THERAPEUTICS, INC. | CAPR | deramiocel |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/capr-20260729xex99d1.htm) |
| August 23, 2026 | Ultragenyx Pharmaceutical Inc. | RARE | pariglasgene brecaparvovec | glycogen storage disease type Ia | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526062568/rare-20260223.htm) |
| August 24, 2026 | CAPRICOR THERAPEUTICS, INC. | CAPR | deramiocel |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824x8k.htm) |
| August 25, 2026 | Jazz Pharmaceuticals plc | JAZZ | Ziihera® (zanidatamab) | with first-line | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm) |
| August 25, 2026 | Royalty Pharma plc | RPRX |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm) |
| August 25, 2026 | Jazz Pharmaceuticals plc | JAZZ |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm) |
| August 27, 2026 | GILEAD SCIENCES, INC. | GILD | bictegravir |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm) |

## All catalysts in August 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 2, 2026 | [Opdivo® (nivolumab) PDUFA date](https://sec-api.dev/pdufa/nivolumab) | REPL |  | completed, approved | "On June 26, 2026 we announced the FDA accepted the BLA resubmission as a Class 1 resubmission with an action date of August 2, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm)) |
| August 2, 2026 | [Replimune Group, Inc. PDUFA date](https://sec-api.dev/companies/repl/catalysts) | REPL |  | scheduled | "The FDA considers this a complete, class 1 response with a goal date of August 2, 2026, and has notified the company to expect an advisory committee meeting in late July." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926078009/tm2619037d1_ex99-1.htm)) |
| August 3, 2026 | [Stoke Therapeutics, Inc. earnings report](https://sec-api.dev/companies/stok/catalysts) | STOK |  | completed | "Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/stok-ex99_1.htm)) |
| August 3, 2026 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm)) |
| August 3, 2026 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm)) |
| August 3, 2026 | [CRISPR Therapeutics AG earnings report](https://sec-api.dev/companies/crsp/catalysts) | CRSP |  | completed | "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/crsp-ex99_1.htm)) |
| August 3, 2026 | [Twist Bioscience Corp earnings report](https://sec-api.dev/companies/twst/catalysts) | TWST |  | completed | "Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581280/000158128026000044/twst-2026630xex991.htm)) |
| August 3, 2026 | [Keros Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kros/catalysts) | KROS |  | completed | "Keros Therapeutics Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000048/exhibit991q22026.htm)) |
| August 3, 2026 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_ex99-1.htm)) |
| August 3, 2026 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312526329520/d118566dex991.htm)) |
| August 3, 2026 | [Seaport Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sptx/catalysts) | SPTX |  | completed | "Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/sptx-ex99_1.htm)) |
| August 3, 2026 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000119312526329570/dsgn-ex99_1.htm)) |
| August 3, 2026 | [Editas Medicine, Inc. earnings report](https://sec-api.dev/companies/edit/catalysts) | EDIT |  | completed | "Editas Medicine Announces Second Quarter 2026 Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000082/editasmedicinepressrelease.htm)) |
| August 3, 2026 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, August 3, 2026 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company" or "Krystal") (NASDAQ: KRYS) today reported financial results for the second quarter ended June 30, 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/a2q26-ex991xpressrelease.htm)) |
| August 3, 2026 | [Oric Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/oric/catalysts) | ORIC |  | completed | "ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330568/oric-ex99_1.htm)) |
| August 3, 2026 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)) |
| August 3, 2026 | [Efinopegdutide primary completion](https://sec-api.dev/pdufa/efinopegdutide) | MRK | Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD | completed | "NCT06465186 (A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465186)) |
| August 3, 2026 | [Eltrekibart primary completion](https://sec-api.dev/pdufa/eltrekibart) | LLY | Ulcerative Colitis; Ulcerative Colitis Chronic | completed | "NCT06598943 (A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06598943)) |
| August 3, 2026 | [LIPFENDRA (enlicitide) primary completion](https://sec-api.dev/pdufa/enlicitide) | MRK | Hyperlipidemia | completed | "NCT07216482 (A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216482)) |
| August 4, 2026 | [Nuvectis Pharma, Inc. earnings report](https://sec-api.dev/companies/nvct/catalysts) | NVCT |  | completed | "2026, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today reported its financial results for the second quarter of 2026 and provided an update on recent business progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1875558/000110465926090094/tm2622125d1_ex99-1.htm)) |
| August 4, 2026 | [TRUSELTIQ® (infigratinib) NDA/BLA submission](https://sec-api.dev/pdufa/infigratinib) | BBIO |  | completed | "•On August 4, 2026, we submitted our NDA to the FDA for low-dose infigratinib for achondroplasia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm)) |
| August 4, 2026 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526331381/idya-ex99_1.htm)) |
| August 4, 2026 | [ARROWHEAD PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/arwr/catalysts) | ARWR |  | completed | "Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000087940726000058/arwr-202608048kex991.htm)) |
| August 4, 2026 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-ex99_1.htm)) |
| August 4, 2026 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "August 4, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000077/ibrx-202684x8kexhibit991.htm)) |
| August 4, 2026 | [CUMBERLAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/cpix/catalysts) | CPIX |  | completed | "(Tuesday, August 04, 2026) - Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful closing of its Strategic Transaction with Apotex Health." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000058/a2026q2-ex991er.htm)) |
| August 4, 2026 | [OnKure Therapeutics, Inc. earnings report](https://sec-api.dev/companies/okur/catalysts) | OKUR |  | completed | "OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1637715/000119312526332809/okur-ex99_1.htm)) |
| August 4, 2026 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815426000124/amgn-20260630earningsrelea.htm)) |
| August 4, 2026 | [Dianthus Therapeutics, Inc. /DE/ earnings report](https://sec-api.dev/companies/dnth/catalysts) | DNTH |  | completed | "AND REPORTS Q2 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/dnth-ex99_1.htm)) |
| August 4, 2026 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/q22026earningsrelease.htm)) |
| August 4, 2026 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312526332752/tyra-ex99_1.htm)) |
| August 4, 2026 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm)) |
| August 4, 2026 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/a2026q2_8-kxex991.htm)) |
| August 4, 2026 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/acad-ex99_1.htm)) |
| August 4, 2026 | [KEYTRUDA® (pembrolizumab) FDA approval](https://sec-api.dev/pdufa/pembrolizumab) | PFE | muscle-invasive bladder cancer | completed, approved | "Pfizer and Astellas Pharma Inc. announced FDA approval of Padcev plus pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as neoadjuvant and adjuvant (before and after surgery) treatment for adult patients with muscle-invasive bladder cancer (MIBC) regardless of cisplatin eligibility." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm)) |
| August 4, 2026 | [BEAM-302 earnings report](https://sec-api.dev/pdufa/beam-302) | BEAM |  | completed | "Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-ex99_1.htm)) |
| August 4, 2026 | [KANJINTI® (trastuzumab) FDA approval](https://sec-api.dev/pdufa/trastuzumab) | PFE |  | completed, approved | "Announced FDA approval of Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer (MBC) following induction treatment based on data from the collaborative Phase 3 PATINA trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm)) |
| August 4, 2026 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm)) |
| August 4, 2026 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-ex99_1.htm)) |
| August 4, 2026 | [Yeztugo® (lenacapavir) NDA/BLA acceptance](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed | "•Announced U.S. Food and Drug Administration ("FDA") accepted a supplemental New Drug Application submission for Yeztugo® (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis ("PrEP"), with a Prescription Drug User Fee Act target action date of February 2, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm)) |
| August 4, 2026 | [PFIZER INC label expansion decision](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed, approved | "Announced the U.S. Food and Drug Administration (FDA) approved an expanded indication for Hympavzi to include the treatment of patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm)) |
| August 4, 2026 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026052170/q22026earningspr_draft.htm)) |
| August 4, 2026 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Bala Cynwyd, PA, August 4, 2026 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2026 operating and financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-ex99_1.htm)) |
| August 4, 2026 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/spyre-20260630xexx991.htm)) |
| August 4, 2026 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/sndx-ex99_1.htm)) |
| August 4, 2026 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/pcrx-06302026x991.htm)) |
| August 4, 2026 | [Odyssey Therapeutics, Inc. earnings report](https://sec-api.dev/companies/odtx/catalysts) | ODTX |  | completed | "Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1882782/000119312526331512/odtx-ex99_1.htm)) |
| August 4, 2026 | [Lipocine Inc. earnings report](https://sec-api.dev/companies/lpcn/catalysts) | LPCN |  | completed | "Announces Financial Results for the Second Quarter Ended June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1535955/000149315226035913/ex99-1.htm)) |
| August 4, 2026 | [PRECIGEN, INC. earnings report](https://sec-api.dev/companies/pgen/catalysts) | PGEN |  | completed | "Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced second quarter 2026 financial results and business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1356090/000095010326011876/dp251262_ex9901.htm)) |
| August 4, 2026 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Rigel Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000053/rigl-20260804xex991q22026r.htm)) |
| August 4, 2026 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm)) |
| August 4, 2026 | [Faeth Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fth/catalysts) | FTH |  | completed | "Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1829802/000119312526331563/d168633dex991.htm)) |
| August 4, 2026 | [BEAM-302 trial start](https://sec-api.dev/pdufa/beam-302) | BEAM |  | completed | "Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-ex99_1.htm)) |
| August 4, 2026 | [Qfitlia™ (fitusiran) primary completion](https://sec-api.dev/pdufa/fitusiran) | SNY | Hemophilia | completed | "NCT03974113 (Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-08-04 (ACTUAL); Lead Sponsor Genzyme, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03974113)) |
| August 4, 2026 | [Barzolvolimab primary completion](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Chronic Spontaneous Urticaria | completed | "NCT06455202 (A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-04 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06455202)) |
| August 4, 2026 | [CERUS CORP topline data readout](https://sec-api.dev/companies/cers/catalysts) | CERS | Healthy Subjects | completed | "NCT06697223 (A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-02 (ACTUAL); Lead Sponsor Cerus Corporation; Results First Posted 2026-08-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06697223?tab=results)) |
| August 5, 2026 | [Tenaya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tnya/catalysts) | TNYA |  | completed | "Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858848/000119312526335098/tnya-ex99_1.htm)) |
| August 5, 2026 | [MIMRYLO™ (rusfertide) NDA/BLA acceptance](https://sec-api.dev/pdufa/rusfertide) | PTGX |  | completed | "As announced on March 2nd, the NDA for rusfertide was accepted by the FDA and granted Priority Review in Q1 2026, with a PDUFA goal date in August 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm)) |
| August 5, 2026 | [Ginkgo Bioworks Holdings, Inc. earnings report](https://sec-api.dev/companies/dna/catalysts) | DNA |  | completed | "Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830214/000162828026053319/ex991earningspr.htm)) |
| August 5, 2026 | [ICOTYDE (icotrokinra) FDA approval](https://sec-api.dev/pdufa/icotrokinra) | PTGX |  | completed, approved | "March 18, Protagonist announced that Johnson & Johnson received U.S. FDA approval of ICOTYDE for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm)) |
| August 5, 2026 | [BioAge Labs, Inc. earnings report](https://sec-api.dev/companies/bioa/catalysts) | BIOA |  | completed | "BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm)) |
| August 5, 2026 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm)) |
| August 5, 2026 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000067/sdgr-20260630x8kxexx991.htm)) |
| August 5, 2026 | [Black Diamond Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bdtx/catalysts) | BDTX |  | completed | "Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000023/bdtx-exhibit991_q22026.htm)) |
| August 5, 2026 | [Intismeran PDUFA date](https://sec-api.dev/pdufa/intismeran) | MRNA |  | scheduled | "The U.S. FDA has assigned a PDUFA date for mRNA-1010 of August 5, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm)) |
| August 5, 2026 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036126031423/ef20079311_ex99-1.htm)) |
| August 5, 2026 | [Enliven Therapeutics, Inc. earnings report](https://sec-api.dev/companies/elvn/catalysts) | ELVN |  | completed | "Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672619/000119312526335101/elvn-ex99_1.htm)) |
| August 5, 2026 | [RASONQUE (daraxonrasib) NDA/BLA acceptance](https://sec-api.dev/pdufa/daraxonrasib) | RVMD | with previously treated metastatic PDAC | completed | "Following the unprecedented Phase 3 results from RASolute 302, the company announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for daraxonrasib for the treatment of patients with previously treated metastatic PDAC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1628171/000119312526335039/rvmd-ex99_1.htm)) |
| August 5, 2026 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "Royalty Pharma reports second quarter 2026 results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260630rpplcpressxre.htm)) |
| August 5, 2026 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm)) |
| August 5, 2026 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/q22026pr.htm)) |
| August 5, 2026 | [Adicet Bio, Inc. earnings report](https://sec-api.dev/companies/acet/catalysts) | ACET |  | completed | "Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/acet-ex99_1.htm)) |
| August 5, 2026 | [Elanco Animal Health Inc earnings report](https://sec-api.dev/companies/elan/catalysts) | ELAN |  | completed | "Elanco Animal Health Reports Second Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739104/000173910426000040/elanco-20260630exhibit991.htm)) |
| August 5, 2026 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255426000028/uthrq22026-ex991.htm)) |
| August 5, 2026 | [Sarepta Therapeutics, Inc. earnings report](https://sec-api.dev/companies/srpt/catalysts) | SRPT |  | completed | "Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/srpt-ex99_1.htm)) |
| August 5, 2026 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805xex99d1.htm)) |
| August 5, 2026 | [Xencor Inc earnings report](https://sec-api.dev/companies/xncr/catalysts) | XNCR |  | completed | "Xencor Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805xexx991.htm)) |
| August 5, 2026 | [Q32 Bio Inc. earnings report](https://sec-api.dev/companies/qttb/catalysts) | QTTB |  | completed | "Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661998/000119312526333813/qttb-ex99_1.htm)) |
| August 5, 2026 | [AbCellera Biologics Inc. earnings report](https://sec-api.dev/companies/abcl/catalysts) | ABCL |  | completed | "VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000044/q22026earningspressrelease.htm)) |
| August 5, 2026 | [CHARLES RIVER LABORATORIES INTERNATIONAL, INC. earnings report](https://sec-api.dev/companies/crl/catalysts) | CRL |  | completed | "Charles River Laboratories Announces Second-Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1100682/000110068226000115/crl2q26earningsrelease.htm)) |
| August 5, 2026 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm)) |
| August 5, 2026 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-ex99_1.htm)) |
| August 5, 2026 | [PERRIGO Co plc earnings report](https://sec-api.dev/companies/prgo/catalysts) | PRGO |  | completed | "Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000143/cy26q2ex991pressrelease.htm)) |
| August 5, 2026 | [UroGen Pharma Ltd. earnings report](https://sec-api.dev/companies/urgn/catalysts) | URGN |  | completed | "PRINCETON, N.J. Aug 5, 2026-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/ex_995856.htm)) |
| August 5, 2026 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/kymr-ex99_1.htm)) |
| August 5, 2026 | [LIFECORE BIOMEDICAL, INC. \DE\ earnings report](https://sec-api.dev/companies/lfcr/catalysts) | LFCR |  | completed | "Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000032/lfcr-2026q2xex991earningsr.htm)) |
| August 5, 2026 | [STANDARD BIOTOOLS INC. earnings report](https://sec-api.dev/companies/lab/catalysts) | LAB |  | completed | "Standard BioTools Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1162194/000119312526335106/lab-ex99_1.htm)) |
| August 5, 2026 | [Ebribafusp trial start](https://sec-api.dev/pdufa/ebribafusp) | AKBA |  | completed | "•In August, Akebia announced that it initiated a Phase 2 open-label basket trial of ebribafusp (previously known as AKB-097 and ADX-097), a next-generation complement inhibitor." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/q22026pr.htm)) |
| August 5, 2026 | [RAP-219 earnings report](https://sec-api.dev/pdufa/rap-219) | RAPP |  | completed | "BOSTON and SAN DIEGO, August 5, 2026 - Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending June 30, 2026, and highlighted continued progress across the RAP-219 development program and pipeline." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-ex99_1.htm)) |
| August 5, 2026 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm)) |
| August 5, 2026 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312526333820/d124829dex991.htm)) |
| August 5, 2026 | [Vir Biotechnology, Inc. earnings report](https://sec-api.dev/companies/vir/catalysts) | VIR |  | completed | "Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1706431/000162828026053351/a20260805-q2ex991earningsr.htm)) |
| August 5, 2026 | [Arcus Biosciences, Inc. earnings report](https://sec-api.dev/companies/rcus/catalysts) | RCUS |  | completed | "Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm)) |
| August 5, 2026 | [Entrada Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trda/catalysts) | TRDA |  | completed | "Entrada Therapeutics Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000052/trdaq22026earningsrelease.htm)) |
| August 5, 2026 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/mnkd-ex99_1.htm)) |
| August 5, 2026 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm)) |
| August 5, 2026 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/exhibit991-q0226.htm)) |
| August 5, 2026 | [EXELIXIS, INC. earnings report](https://sec-api.dev/companies/exel/catalysts) | EXEL |  | completed | "Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm)) |
| August 5, 2026 | [ZEVRA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/zvra/catalysts) | ZVRA |  | completed | "Zevra Reports Second Quarter 2026 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000067/zvra-20260805xex991earnings.htm)) |
| August 5, 2026 | [Atebimetinib trial start](https://sec-api.dev/pdufa/atebimetinib) | IMRX |  | completed | "In June, Immuneering announced it had dosed the first patient in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm)) |
| August 5, 2026 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000119312526335192/d228097dex991.htm)) |
| August 5, 2026 | [Revolution Medicines, Inc. earnings report](https://sec-api.dev/companies/rvmd/catalysts) | RVMD |  | completed | "Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1628171/000119312526335039/rvmd-ex99_1.htm)) |
| August 5, 2026 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000112/mlys2026q28kex991.htm)) |
| August 5, 2026 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000044/mirm-20260805xexx991.htm)) |
| August 5, 2026 | [ImageneBio, Inc. earnings report](https://sec-api.dev/companies/ima/catalysts) | IMA |  | completed | "ImageneBio Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835579/000119312526333912/d166048dex991.htm)) |
| August 5, 2026 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000080/ebs202606-30ex99er.htm)) |
| August 5, 2026 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/exhibit991-q22026earningsr.htm)) |
| August 5, 2026 | [Vaxcyte, Inc. earnings report](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed | "Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805xexx991.htm)) |
| August 5, 2026 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm)) |
| August 5, 2026 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000119312526336508/d158179dex991.htm)) |
| August 5, 2026 | [Zomedica Corp. earnings report](https://sec-api.dev/companies/zomdf/catalysts) | ZOMDF |  | completed | "ANN ARBOR, MI / ACCESSWIRE / August 5, 2026 / Zomedica Corp. (OTCQB: ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the three and six months ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1684144/000165495426007306/zom_ex991.htm)) |
| August 5, 2026 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000162828026053384/q22026eolsex991.htm)) |
| August 5, 2026 | [Korro Bio, Inc. earnings report](https://sec-api.dev/companies/krro/catalysts) | KRRO |  | completed | "Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703647/000119312526336685/krro-ex99_1.htm)) |
| August 5, 2026 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Coeliac Disease; Celiac Disease | completed | "NCT06557772 (A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-05 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06557772)) |
| August 5, 2026 | [RAP-219 primary completion](https://sec-api.dev/pdufa/rap-219) | RAPP | Bipolar 1 Disorder | completed | "NCT07046494 (Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-05 (ACTUAL); Lead Sponsor Rapport Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07046494)) |
| August 5, 2026 | [ORZEYFUL (oveporexton) FDA approval](https://sec-api.dev/pdufa/oveporexton) | TAK | To treat narcolepsy type 1 | completed, approved | "Orzeyful \| oveporexton \| 8/5/2026 \| To treat narcolepsy type 1" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| August 6, 2026 | [Avalo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/avtx/catalysts) | AVTX |  | completed | "Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000048/ex-9912q2026earningsrelease.htm)) |
| August 6, 2026 | [Sionna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sion/catalysts) | SION |  | completed | "Sionna Therapeutics Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2036042/000162828026053832/sion2q26earningsrelease_fi.htm)) |
| August 6, 2026 | [Lineage Cell Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lctx/catalysts) | LCTX |  | completed | "LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/876343/000119312526338020/lctx-ex99_1.htm)) |
| August 6, 2026 | [Opdivo® (nivolumab) FDA approval](https://sec-api.dev/pdufa/nivolumab) | REPL | with unresectable advanced cutaneous melanoma | completed, approved | "On August 6, 2026, we announced that the FDA has granted accelerated approval of TUDRIQEV in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm)) |
| August 6, 2026 | [Aurinia Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/auph/catalysts) | AUPH |  | completed | "Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1600620/000160062026000059/exhibit991_q22026earningsr.htm)) |
| August 6, 2026 | [NATURES SUNSHINE PRODUCTS INC earnings report](https://sec-api.dev/companies/natr/catalysts) | NATR |  | completed | "Nature's Sunshine Reports Second Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/275053/000162828026054387/natrq22026earningsrelease.htm)) |
| August 6, 2026 | [PRECISION BIOSCIENCES INC earnings report](https://sec-api.dev/companies/dtil/catalysts) | DTIL |  | completed | "Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357874/000162828026053836/q22026earningsrelease_final.htm)) |
| August 6, 2026 | [OmniAb, Inc. earnings report](https://sec-api.dev/companies/oabi/catalysts) | OABI |  | completed | "OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1846253/000184625326000044/a2026q2ex991.htm)) |
| August 6, 2026 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000045/amph-20260806xex99d1.htm)) |
| August 6, 2026 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports Second-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/exhibit991-2q26earningsrel.htm)) |
| August 6, 2026 | [Surrozen, Inc./DE earnings report](https://sec-api.dev/companies/srzn/catalysts) | SRZN |  | completed | "Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824893/000119312526338068/srzn-ex99_1.htm)) |
| August 6, 2026 | [Cartesian Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rnac/catalysts) | RNAC |  | completed | "Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000100/exhibit991_earningsrelease.htm)) |
| August 6, 2026 | [MBX Biosciences, Inc. earnings report](https://sec-api.dev/companies/mbx/catalysts) | MBX |  | completed | "MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000119312526336841/mbx-ex99_1.htm)) |
| August 6, 2026 | [Climb Bio, Inc. earnings report](https://sec-api.dev/companies/clym/catalysts) | CLYM |  | completed | "Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768446/000119312526336762/clym-ex99_1.htm)) |
| August 6, 2026 | [Tectonic Therapeutic, Inc. earnings report](https://sec-api.dev/companies/tecx/catalysts) | TECX |  | completed | "Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1681087/000119312526338000/d114671dex991.htm)) |
| August 6, 2026 | [Viatris Inc FDA approval](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed, approved | "•In July, the Company announced that the U.S. Food and Drug Administration (FDA) approved Gwyn LoTM (norelgestromin and ethinyl estradiol transdermal system), a new combined hormonal contraceptive patch with low-dose estrogen." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/exhibit991-2q26earningsrel.htm)) |
| August 6, 2026 | [RELMADA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/rlmd/catalysts) | RLMD |  | completed | "PRESS RELEASE DATED AUGUST 6, 2026, REGARDING A CORPORATE UPDATE AND REPORTING ITS FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/ea030099301ex99-1.htm)) |
| August 6, 2026 | [Prime Medicine, Inc. earnings report](https://sec-api.dev/companies/prme/catalysts) | PRME |  | completed | "Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1894562/000162828026053878/q220268-kex991xpressrelease.htm)) |
| August 6, 2026 | [Vusolimogene oderparepvec FDA approval](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL | with unresectable advanced cutaneous melanoma | completed, approved | "August 6, 2026, the Company announced the U.S. Food and Drug Administration (FDA) has approved TUDRIQEV (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression with a PD-1 antibody-based regimen." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926096483/tm2623208d1_ex99-1.htm)) |
| August 6, 2026 | [Roivant Sciences Ltd. earnings report](https://sec-api.dev/companies/roiv/catalysts) | ROIV |  | completed | "Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm)) |
| August 6, 2026 | [Phio Pharmaceuticals Corp. earnings report](https://sec-api.dev/companies/phio/catalysts) | PHIO |  | completed | "Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1533040/000143774926026275/ex_965504.htm)) |
| August 6, 2026 | [Generate Biomedicines, Inc. earnings report](https://sec-api.dev/companies/genb/catalysts) | GENB |  | completed | "Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2100782/000119312526336462/ck0002100782-ex99_1.htm)) |
| August 6, 2026 | [Verastem, Inc. trial start](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | completed | "July 28, July 22, and June 16, the Company announced the first patient was dosed in the TARGET-D" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/tm2622452d2_ex99-1.htm)) |
| August 6, 2026 | [VTv Therapeutics Inc. earnings report](https://sec-api.dev/companies/vtvt/catalysts) | VTVT |  | completed | "Exhibit 99.1 vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641489/000164148926000029/vtvt-20260630xexx991pressr.htm)) |
| August 6, 2026 | [PROTHENA CORP PUBLIC LTD CO earnings report](https://sec-api.dev/companies/prta/catalysts) | PRTA |  | completed | "Prothena Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1559053/000155905326000021/exhibit991q22026earningsre.htm)) |
| August 6, 2026 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000103/ex991q220268-k.htm)) |
| August 6, 2026 | [Zentalis Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/zntl/catalysts) | ZNTL |  | completed | "Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1725160/000172516026000061/zntlq22026pressrelease.htm)) |
| August 6, 2026 | [CytomX Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctmx/catalysts) | CTMX |  | completed | "CytomX Therapeutics Announces Q2 2026 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501989/000119312526338009/ctmx-ex99_1.htm)) |
| August 6, 2026 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/d13828dex991.htm)) |
| August 6, 2026 | [Compass Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cmpx/catalysts) | CMPX |  | completed | "Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm)) |
| August 6, 2026 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000041/q22026earningsrelease_ex991.htm)) |
| August 6, 2026 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526336886/ck0001991792-ex99_1.htm)) |
| August 6, 2026 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000096/ex991pressreleaseq22026.htm)) |
| August 6, 2026 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036126031672/ef20079446_ex99-1.htm)) |
| August 6, 2026 | [PepGen Inc. earnings report](https://sec-api.dev/companies/pepg/catalysts) | PEPG |  | completed | "PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835597/000119312526336767/pepg-ex99_1.htm)) |
| August 6, 2026 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926091629/acrs-20260806xex99d1.htm)) |
| August 6, 2026 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000119312526338022/orgo-ex99_1.htm)) |
| August 6, 2026 | [Xenon Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/xene/catalysts) | XENE |  | completed | "Xenon Reports Q2 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526338019/xene-ex99_1.htm)) |
| August 6, 2026 | [Zymeworks Inc. earnings report](https://sec-api.dev/companies/zyme/catalysts) | ZYME |  | completed | "Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/ex991q22026_earningsxrelea.htm)) |
| August 6, 2026 | [REVELATION BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/revb/catalysts) | REVB |  | completed | "Revelation Biosciences, Inc. Announces Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810560/000119312526338097/revb-ex99_1.htm)) |
| August 6, 2026 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526336716/rgnx-ex99_1.htm)) |
| August 6, 2026 | [Evommune, Inc. earnings report](https://sec-api.dev/companies/evmn/catalysts) | EVMN |  | completed | "Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337964/evmn-ex99_1.htm)) |
| August 6, 2026 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/ex_1000406.htm)) |
| August 6, 2026 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126031502/ef20079469_ex99-1.htm)) |
| August 6, 2026 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326005317/exh_991.htm)) |
| August 6, 2026 | [Structure Therapeutics Inc. trial start](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "The Company announced that the first patients have been dosed in the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/tm2622407d1_ex99-1.htm)) |
| August 6, 2026 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/exh991q22026earningsrelease.htm)) |
| August 6, 2026 | [VOXZOGO (vosoritide) NDA/BLA acceptance](https://sec-api.dev/pdufa/vosoritide) | BMRN | achondroplasia | completed | "•In July, BioMarin announced that the FDA accepted its sNDA for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm)) |
| August 6, 2026 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/ird-202686xex991.htm)) |
| August 6, 2026 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported second quarter 2026 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/tm2622368d1_ex99-1.htm)) |
| August 6, 2026 | [Lyell Immunopharma, Inc. earnings report](https://sec-api.dev/companies/lyel/catalysts) | LYEL |  | completed | "Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806952/000162828026054330/lyel-20260806x8kexx991.htm)) |
| August 6, 2026 | [COLLEGIUM PHARMACEUTICAL, INC earnings report](https://sec-api.dev/companies/coll/catalysts) | COLL |  | completed | "Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1267565/000162828026053849/coll-2026x06x30xex99x1.htm)) |
| August 6, 2026 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/amlx-ex99_1.htm)) |
| August 6, 2026 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports second quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000167192726000020/pressrelease-q22026.htm)) |
| August 6, 2026 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Press Release Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/prfinal.htm)) |
| August 6, 2026 | [Verastem, Inc. earnings report](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | completed | "Aug. 6, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/tm2622452d2_ex99-1.htm)) |
| August 6, 2026 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/glue-ex99_1.htm)) |
| August 6, 2026 | [LEXICON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/lxrx/catalysts) | LXRX |  | completed | "The Woodlands, Texas, August 6, 2026 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282226000112/pressreleaseearningsq208-0.htm)) |
| August 6, 2026 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "WALTHAM, Mass. - August 6, 2026 - Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744dex991.htm)) |
| August 6, 2026 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/ex_973970.htm)) |
| August 6, 2026 | [Alector, Inc. earnings report](https://sec-api.dev/companies/alec/catalysts) | ALEC |  | completed | "Alector Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1653087/000119312526338008/alec-ex99_1.htm)) |
| August 6, 2026 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-ex99_1.htm)) |
| August 6, 2026 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm)) |
| August 6, 2026 | [IN8BIO, INC. earnings report](https://sec-api.dev/companies/inab/catalysts) | INAB |  | completed | "IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1740279/000119312526337944/inab-ex99_1.htm)) |
| August 6, 2026 | [ALX ONCOLOGY HOLDINGS INC earnings report](https://sec-api.dev/companies/alxo/catalysts) | ALXO |  | completed | "ALX Oncology Reports Second Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810182/000119312526336843/alxo-ex99_1.htm)) |
| August 6, 2026 | [Aligos Therapeutics, Inc. earnings report](https://sec-api.dev/companies/algs/catalysts) | ALGS |  | completed | "Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/exh_991.htm)) |
| August 6, 2026 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_ex99-1.htm)) |
| August 6, 2026 | [Cryoport, Inc. earnings report](https://sec-api.dev/companies/cyrx/catalysts) | CYRX |  | completed | "or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124524/000110465926092064/tm2622464d1_ex99-1.htm)) |
| August 6, 2026 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000119312526336780/agen-ex99_1.htm)) |
| August 6, 2026 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465926091625/tm2622244d1_ex99-1.htm)) |
| August 6, 2026 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/e665684_ex99-2.htm)) |
| August 6, 2026 | [MARAVAI LIFESCIENCES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/mrvi/catalysts) | MRVI |  | completed | "MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1823239/000182323926000056/exhibit991-q22026.htm)) |
| August 6, 2026 | [Prestige Consumer Healthcare Inc. earnings report](https://sec-api.dev/companies/pbh/catalysts) | PBH |  | completed | "Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1295947/000129594726000040/exhibit991fy27-q1earningsr.htm)) |
| August 6, 2026 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm)) |
| August 6, 2026 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/exhibit991tarsus862026.htm)) |
| August 6, 2026 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm)) |
| August 6, 2026 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312526337069/whwk-ex99_1.htm)) |
| August 6, 2026 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "(Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926091671/tm2621653d1_ex99-1.htm)) |
| August 6, 2026 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000043/ardx-20260630xexhibit991.htm)) |
| August 6, 2026 | [Zoetis Inc. earnings report](https://sec-api.dev/companies/zts/catalysts) | ZTS |  | completed | "Zoetis Announces Second Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1555280/000155528026000038/exhibit99q22026.htm)) |
| August 6, 2026 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm)) |
| August 6, 2026 | [COGNITION THERAPEUTICS INC earnings report](https://sec-api.dev/companies/cgtx/catalysts) | CGTX |  | completed | "Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1455365/000110465926092037/tm2622462d1_ex99-1.htm)) |
| August 6, 2026 | [Corbus Pharmaceuticals Holdings, Inc. earnings report](https://sec-api.dev/companies/crbp/catalysts) | CRBP |  | completed | "Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/crbp-ex99_1.htm)) |
| August 6, 2026 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312526337977/janx-ex99_1.htm)) |
| August 6, 2026 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526336751/d261840dex991.htm)) |
| August 6, 2026 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926092025/nxtc-20260806xex99d1.htm)) |
| August 6, 2026 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/mtva-20260806xex99d1.htm)) |
| August 6, 2026 | [Relay Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rlay/catalysts) | RLAY |  | completed | "Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1812364/000119312526338013/rlay-ex99_2.htm)) |
| August 6, 2026 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "SHANGHAI & CAMBRIDGE, Mass., August 6, 2026 -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2026, along with recent product highlights and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm)) |
| August 6, 2026 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000119312526337986/artv-ex99_1.htm)) |
| August 6, 2026 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the second quarter ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/tm2622407d1_ex99-1.htm)) |
| August 6, 2026 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "CARLOS, Calif., August 6, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter 2026 financial results, business achievements, and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_ex99-1.htm)) |
| August 6, 2026 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "SAN RAFAEL, Calif., August 6, 2026 - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm)) |
| August 6, 2026 | [Trevi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trvi/catalysts) | TRVI |  | completed | "Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1563880/000119312526337974/trvi-ex99_1.htm)) |
| August 6, 2026 | [Lipfendra (enlicitide decanoate) topline data readout](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hypercholesterolemia; Familial Hypercholesterolemia | completed | "NCT05952856 (A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952856?tab=results)) |
| August 6, 2026 | [Baxfendy (baxdrostat) topline data readout](https://sec-api.dev/pdufa/baxdrostat) | AZN | Resistant Hypertension | completed | "NCT06168409 (A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-17 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-08-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06168409?tab=results)) |
| August 6, 2026 | [Ints-gmma dose c primary completion](https://sec-api.dev/pdufa/ints-gmma) | GSK | Salmonella Infections | completed | "NCT06213506 (A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-06 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06213506)) |
| August 6, 2026 | [Bezisterim primary completion](https://sec-api.dev/pdufa/bezisterim) | BIVI | Long COVID | completed | "NCT06847191 (NE3107 in Adults With Neurological Symptoms of Long COVID): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-06 (ACTUAL); Lead Sponsor BioVie Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06847191)) |
| August 6, 2026 | [SAR441566 primary completion](https://sec-api.dev/pdufa/sar441566) | SNY | Colitis Ulcerative | withdrawn | "NCT06867094 (A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-08-06 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06867094)) |
| August 7, 2026 | [KIORA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/kprx/catalysts) | KPRX |  | completed | "Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000075/ex991-pressreleasejune3020.htm)) |
| August 7, 2026 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000068/anip-20260807xexx991.htm)) |
| August 7, 2026 | [ATOSSA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/atos/catalysts) | ATOS |  | completed | "Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1488039/000119312526339292/atos-ex99_1.htm)) |
| August 7, 2026 | [ITM-11 complete response letter (CRL)](https://sec-api.dev/pdufa/itm-11) | TLX |  | completed, complete response letter | "ITM-11 U.S. regulatory status CRL received on August 7, 2026 is limited to CMC and third-party facility items and no clinical or nonclinical deficiencies were identified CRL scope FDA cited Chemistry, Manufacturing and Controls (CMC) and third-party commercial facility inspection- related items Clinical package No clinical safety or efficacy issues were identified, and no additional clinical or nonclinical data were requested Remediation ITM is reviewing the feedback and coordinating with relevant external parties to address the cited items Resubmission ITM intends to resubmit the NDA to complete FDA review; timing remains subject to remediation and agency interaction." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026068291/a20261030tlxnoticeofgene.htm)) |
| August 7, 2026 | [Entera Bio Ltd. earnings report](https://sec-api.dev/companies/entx/catalysts) | ENTX |  | completed | "ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported financial results and key business updates for the quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638097/000117891326003946/exhibit_99-1.htm)) |
| August 7, 2026 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526339223/gyre-ex99_1.htm)) |
| August 7, 2026 | [BioAffinity Technologies, Inc. earnings report](https://sec-api.dev/companies/biaf/catalysts) | BIAF |  | completed | "Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1712762/000149315226036486/ex99-1.htm)) |
| August 7, 2026 | [Xenetic Biosciences, Inc. earnings report](https://sec-api.dev/companies/xbio/catalysts) | XBIO |  | completed | "Reports Second Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534525/000168316826006077/xenetic_ex9901.htm)) |
| August 7, 2026 | [Earth Science Tech, Inc. earnings report](https://sec-api.dev/companies/etst/catalysts) | ETST |  | completed | "Science Tech, Inc. (ETST) Reports Fiscal First Quarter 2027 Financial Results for the Period Ended June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1538495/000149315226036483/ex99-1.htm)) |
| August 7, 2026 | [Ampligen® (rintatolimod) earnings report](https://sec-api.dev/pdufa/rintatolimod) | AIM |  | completed | "ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/946644/000149315226036753/ex99-1.htm)) |
| August 7, 2026 | [Efzofitimod earnings report](https://sec-api.dev/pdufa/efzofitimod) | ATYR |  | completed | "Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-ex99_1.htm)) |
| August 7, 2026 | [JAKAFI (ruxolitinib) primary completion](https://sec-api.dev/pdufa/ruxolitinib) | INCY | Atopic Dermatitis | completed | "NCT06832618 (A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-07 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06832618)) |
| August 10, 2026 | [EDP-978 trial start](https://sec-api.dev/pdufa/edp-978) | ENTA |  | completed | "In April, the Company announced that the first participant was dosed in a randomized, double-blind, placebo-controlled, first-in-human Phase 1 clinical trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm)) |
| August 10, 2026 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-ex99_1.htm)) |
| August 10, 2026 | [Quantum Biopharma Ltd. FDA approval](https://sec-api.dev/companies/qntm/catalysts) | QNTM |  | completed, approved | "TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma"), a transformative biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurological, metabolic, and alcohol misuse disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), enabling Quantum BioPharma to immediately advance its patented, first-in-class multiple sclerosis program into Phase 2 clinical development." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771885/000117184326005370/exh_991.htm)) |
| August 10, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | delayed | "NS Pharma Dispute: The state court was scheduled to hear Capricor's motion for preliminary injunction on August 10, 2026, ahead of the PDUFA action date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813xex99d1.htm)) |
| August 10, 2026 | [Sana Biotechnology, Inc. earnings report](https://sec-api.dev/companies/sana/catalysts) | SANA |  | completed | "Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770121/000119312526342371/sana-ex99_1.htm)) |
| August 10, 2026 | [DiaMedica Therapeutics Inc. earnings report](https://sec-api.dev/companies/dmac/catalysts) | DMAC |  | completed | "DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401040/000143774926026790/ex_1001907.htm)) |
| August 10, 2026 | [Metagenomi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mgx/catalysts) | MGX |  | completed | "Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785279/000119312526342388/mgx-ex99_1.htm)) |
| August 10, 2026 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, August 10, 2026 (Globe NewsWire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/olma-ex99_1.htm)) |
| August 10, 2026 | [Divesiran topline data readout](https://sec-api.dev/pdufa/divesiran) | SLN |  | completed, positive | "On August 10, 2026, Silence reported positive topline results from its Phase 2 SANRECO trial of divesiran, an investigational siRNA therapy silencing TMPRSS6, in polycythemia vera, supporting a potentially best-in-class profile with once-every-three-month dosing." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312526457060/d101909dex991.htm)) |
| August 10, 2026 | [Nkarta, Inc. earnings report](https://sec-api.dev/companies/nktx/catalysts) | NKTX |  | completed | "Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787400/000119312526342402/nktx-ex99_1.htm)) |
| August 10, 2026 | [JADE-002 trial start](https://sec-api.dev/pdufa/jade201) | JBIO | rheumatoid arthritis | completed | "Announced dosing began in the Phase 1 clinical trial evaluating JADE201 in participants with rheumatoid arthritis; interim, biomarker-rich data expected in 2027 are anticipated to inform indication prioritization and a focused clinical development strategy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629dex991.htm)) |
| August 10, 2026 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/d123580dex991.htm)) |
| August 10, 2026 | [Oruka Therapeutics, Inc. earnings report](https://sec-api.dev/companies/orka/catalysts) | ORKA |  | completed | "-- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today reported second quarter 2026 financial results and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/907654/000121390026086933/ea030131201ex99-1.htm)) |
| August 10, 2026 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm)) |
| August 10, 2026 | [Attruby (acoramidis) earnings report](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed | "PALO ALTO, Calif., August 10, 2026 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the second quarter ended June 30, 2026, and provided an update on Attruby's commercial progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm)) |
| August 10, 2026 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000119312526341300/hrtx-ex99_1.htm)) |
| August 10, 2026 | [JADE-001 trial start](https://sec-api.dev/pdufa/jade101) | JBIO |  | completed | "Announced dosing began in JUNIPER, a Phase 2 trial of JADE101 in IgAN." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629dex991.htm)) |
| August 10, 2026 | [PALI-2108 earnings report](https://sec-api.dev/pdufa/pali-2108) | PALI |  | completed | "Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/pali-ex99_1.htm)) |
| August 10, 2026 | [Jade Biosciences, Inc. earnings report](https://sec-api.dev/companies/jbio/catalysts) | JBIO |  | completed | "Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629dex991.htm)) |
| August 10, 2026 | [Indaptus Therapeutics, Inc. earnings report](https://sec-api.dev/companies/indp/catalysts) | INDP |  | completed | "Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1857044/000149315226037574/ex99-1.htm)) |
| August 10, 2026 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/a2026q2bhvnearningsprex991.htm)) |
| August 10, 2026 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/ex_1002031.htm)) |
| August 10, 2026 | [Perspective Therapeutics, Inc. earnings report](https://sec-api.dev/companies/catx/catalysts) | CATX |  | completed | "SEATTLE - August 10, 2026 - Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/728387/000119312526342495/catx-ex99_1.htm)) |
| August 10, 2026 | [Septerna, Inc. earnings report](https://sec-api.dev/companies/sepn/catalysts) | SEPN |  | completed | "Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1984086/000119312526342328/sepn-ex99_1.htm)) |
| August 10, 2026 | [HARROW, INC. earnings report](https://sec-api.dev/companies/hrow/catalysts) | HROW |  | completed | "Announces Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1360214/000149315226036865/ex99-1.htm)) |
| August 10, 2026 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | completed, positive | "MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive topline results from the Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-na&iuml;ve adults with active psoriatic arthritis (PsA) and reported second quarter 2026 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea030119101ex99-1.htm)) |
| August 10, 2026 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312526342335/vera-ex99_1.htm)) |
| August 10, 2026 | [Bezuclastinib NDA/BLA acceptance](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed | "Announced FDA acceptance of the New Drug Application (NDA) with priority review for bezuclastinib in combination with sunitinib in patients with GIST who have received prior treatment with imatinib." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-ex99_1.htm)) |
| August 10, 2026 | [ABCL635 topline data readout](https://sec-api.dev/pdufa/abcl635) | ABCL | moderate-to-severe vasomotor symptoms | completed, positive | "On August 10, 2026, we announced positive top-line results from the Phase 2 portion of our Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor, or NK3R, antagonist antibody." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1703057/000119312526349333/d112521d424b5.htm)) |
| August 10, 2026 | [Tonix Pharmaceuticals Holding Corp. earnings report](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000149315226036740/ex99-01.htm)) |
| August 10, 2026 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126032028/ef20079821_ex99-1.htm)) |
| August 10, 2026 | [NEO100 (NEO100) earnings report](https://sec-api.dev/pdufa/neo100) | NTHI |  | completed | "NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1979414/000182912626008543/neonctechnologies_ex99-1.htm)) |
| August 10, 2026 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., August 10, 2026 - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-ex99_1.htm)) |
| August 10, 2026 | [Sonelokimab earnings report](https://sec-api.dev/pdufa/sonelokimab) | MLTX |  | completed | "MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea030119101ex99-1.htm)) |
| August 10, 2026 | [PROKIDNEY CORP. earnings report](https://sec-api.dev/companies/prok/catalysts) | PROK |  | completed | "ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850270/000119312526342397/prok-ex99_1.htm)) |
| August 10, 2026 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312526341240/d162225dex991.htm)) |
| August 10, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | completed | "NCT05211895 (A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05211895)) |
| August 10, 2026 | [NEXIUM-20MG primary completion](https://sec-api.dev/pdufa/nexium-20mg) | AZN | Erosive Esophagitis | completed | "NCT05267613 (Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05267613)) |
| August 10, 2026 | [Efgartigimod iv topline data readout](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized | completed | "NCT06298552 (A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor argenx; Results First Posted 2026-08-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06298552?tab=results)) |
| August 10, 2026 | [AZD7798 primary completion](https://sec-api.dev/pdufa/azd7798) | AZN | Crohn's Disease | completed | "NCT06681324 (Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06681324)) |
| August 11, 2026 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315226036985/ex99-1.htm)) |
| August 11, 2026 | [Cardiff Oncology, Inc. earnings report](https://sec-api.dev/companies/crdf/catalysts) | CRDF |  | completed | "Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm)) |
| August 11, 2026 | [Vireo Growth Inc. earnings report](https://sec-api.dev/companies/vreof/catalysts) | VREOF |  | completed | "Vireo Growth Inc. Announces Second Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771706/000110465926093723/vreof-20260811xex99d1.htm)) |
| August 11, 2026 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312526343428/ck0001534133-ex99_1.htm)) |
| August 11, 2026 | [Taysha Gene Therapies, Inc. earnings report](https://sec-api.dev/companies/tsha/catalysts) | TSHA |  | completed | "Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)) |
| August 11, 2026 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312526344580/bolt-ex99_1.htm)) |
| August 11, 2026 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000162828026055484/sttk_2q2026earningsrelease.htm)) |
| August 11, 2026 | [Kyverna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kytx/catalysts) | KYTX |  | completed | "Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000119312526344572/kytx-ex99_1.htm)) |
| August 11, 2026 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/ea029923601ex99-1.htm)) |
| August 11, 2026 | [LB PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lbrx/catalysts) | LBRX |  | completed | "NEW YORK, August 11, 2026 (GLOBE NEWSWIRE) - LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced financial results for the second quarter ended on June 30, 2026 and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1691082/000119312526343479/d303033dex991.htm)) |
| August 11, 2026 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000149315226037124/ex99-1.htm)) |
| August 11, 2026 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465926094041/ganx-20260811xex99d1.htm)) |
| August 11, 2026 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, August 11, 2026 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/exhibit991-2026q210xqpr.htm)) |
| August 11, 2026 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000051/a991q226pressrelease.htm)) |
| August 11, 2026 | [Theriva (theriva) earnings report](https://sec-api.dev/pdufa/theriva) | TOVX |  | completed | "Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/tm2622636d1_ex99-1.htm)) |
| August 11, 2026 | [AN2 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/antx/catalysts) | ANTX |  | completed | "AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1880438/000119312526344549/antx-ex99_1.htm)) |
| August 11, 2026 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-ex99_1.htm)) |
| August 11, 2026 | [Imatinib earnings report](https://sec-api.dev/pdufa/imatinib) | IKT |  | completed | ""Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312526344623/d134059dex991.htm)) |
| August 11, 2026 | [Zabilugene almadenorepvec trial start](https://sec-api.dev/pdufa/zabilugene-almadenorepvec) | TOVX |  | completed | "As recently announced, the first patients have been dosed in the VIRAGE2 Phase 2a clinical trial entitled "A" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/tm2622636d1_ex99-1.htm)) |
| August 11, 2026 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/q22026-ex991earningsrelease.htm)) |
| August 11, 2026 | [Hemab Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/coag/catalysts) | COAG |  | completed | "Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2114044/000119312526343421/d180684dex991.htm)) |
| August 11, 2026 | [Bicara Therapeutics Inc. earnings report](https://sec-api.dev/companies/bcax/catalysts) | BCAX |  | completed | "BOSTON, August 11, 2026 - Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the second quarter ended June 30, 2026 and provided a business update, including strategic leadership transitions marking the company's next era of execution and growth." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026055500/projectwaystar-2q26earning.htm)) |
| August 11, 2026 | [Aura Biosciences, Inc. earnings report](https://sec-api.dev/companies/aura/catalysts) | AURA |  | completed | "Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501796/000119312526343408/aura-ex99_1.htm)) |
| August 11, 2026 | [Coya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/coya/catalysts) | COYA |  | completed | "Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835022/000119312526343473/coya-ex99_1.htm)) |
| August 11, 2026 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526343434/tngx-ex99_1.htm)) |
| August 11, 2026 | [Aardvark Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aard/catalysts) | AARD |  | completed | "Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1774857/000119312526344978/ck0001774857-ex99_1.htm)) |
| August 11, 2026 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Sagimet Biosciences Reports Second Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000119312526343446/d36435dex991.htm)) |
| August 11, 2026 | [TherapeuticsMD, Inc. earnings report](https://sec-api.dev/companies/txmd/catalysts) | TXMD |  | completed | "PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED AUGUST 11, 2026, ENTITLED "THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/25743/000121390026087756/ea029897901ex99-1.htm)) |
| August 11, 2026 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/imnm-ex99_1.htm)) |
| August 11, 2026 | [Eloxx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/elox/catalysts) | ELOX |  | completed | "Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/d167833dex991.htm)) |
| August 11, 2026 | [Neurogene earnings report](https://sec-api.dev/pdufa/neurogene) | NGNE |  | completed | "Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000056/ngne_2qye26earningsrelease.htm)) |
| August 11, 2026 | [C4 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cccc/catalysts) | CCCC |  | completed | "C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/cccc-20260811xexx991.htm)) |
| August 11, 2026 | [Kardigan, Inc. earnings report](https://sec-api.dev/companies/kard/catalysts) | KARD |  | completed | "Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2123613/000119312526343395/ck0002123613-ex99_1.htm)) |
| August 11, 2026 | [BridgeBio Oncology Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bbot/catalysts) | BBOT |  | completed | "BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1869105/000119312526344608/bbot-ex99_1.htm)) |
| August 11, 2026 | [Mereo BioPharma Group plc earnings report](https://sec-api.dev/companies/mreo/catalysts) | MREO |  | completed | "Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719714/000119312526343519/mreo-ex99_1.htm)) |
| August 11, 2026 | [Zura Bio Ltd earnings report](https://sec-api.dev/companies/zura/catalysts) | ZURA |  | completed | "Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855644/000185564426000007/zura-20260811xex991.htm)) |
| August 11, 2026 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_ex99-1.htm)) |
| August 11, 2026 | [AUCATZYL (obecabtagene autoleucel) earnings report](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed | "Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates August 11, 2026 at 7:00 AM EDT Company reports AUCATZYL® (obecabtagene autoleucel" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000119/autlex-991pr110826a01.htm)) |
| August 11, 2026 | [Erasca, Inc. earnings report](https://sec-api.dev/companies/eras/catalysts) | ERAS |  | completed | "Erasca Reports Second Quarter 2026 Business Updates and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761918/000119312526344584/eras-ex99_1.htm)) |
| August 11, 2026 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312526343477/d114296dex991.htm)) |
| August 11, 2026 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-202608118xkexhibit991.htm)) |
| August 11, 2026 | [Upstream Bio, Inc. earnings report](https://sec-api.dev/companies/upb/catalysts) | UPB |  | completed | "Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022626/000119312526343407/upb-ex99_1.htm)) |
| August 11, 2026 | [Veradermics, Inc earnings report](https://sec-api.dev/companies/mane/catalysts) | MANE |  | completed | "Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000028/ex991q226earnings.htm)) |
| August 11, 2026 | [Prelude Therapeutics Inc earnings report](https://sec-api.dev/companies/prld/catalysts) | PRLD |  | completed | "Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1678660/000119312526343469/prld-ex99_1.htm)) |
| August 11, 2026 | [INTENSITY THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ints/catalysts) | INTS |  | completed | "Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000061/ints20260811ex99120260630p.htm)) |
| August 11, 2026 | [PLIANT THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/plrx/catalysts) | PLRX |  | completed | "Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000115/plrx-2026811xexx991.htm)) |
| August 11, 2026 | [Stannous fluoride and potassium nitrate dentifrice primary completion](https://sec-api.dev/pdufa/stannous-fluoride-and-nitrate-dentifrice) | HLN | Dentin Hypersensitivity | completed | "NCT07215767 (Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-11 (ACTUAL); Lead Sponsor HALEON." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215767)) |
| August 12, 2026 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000162828026055940/abos-20260812xexx991.htm)) |
| August 12, 2026 | [MAXCYTE, INC. earnings report](https://sec-api.dev/companies/mxct/catalysts) | MXCT |  | completed | "MaxCyte Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1287098/000110465926094886/mxct-20260812xex99d1.htm)) |
| August 12, 2026 | [Atea Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/avir/catalysts) | AVIR |  | completed | "Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1593899/000119312526346888/d165663dex991.htm)) |
| August 12, 2026 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312526346857/atra-ex99_1.htm)) |
| August 12, 2026 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088061/ea030169901ex99-1.htm)) |
| August 12, 2026 | [Turn Therapeutics Inc. earnings report](https://sec-api.dev/companies/ttrx/catalysts) | TTRX |  | completed | "Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023016/000121390026088411/ea030177201ex99-1.htm)) |
| August 12, 2026 | [Arbutus Biopharma Corp earnings report](https://sec-api.dev/companies/abus/catalysts) | ABUS |  | completed | "Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1447028/000117184326005442/exh_991.htm)) |
| August 12, 2026 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., Aug 12, 2026 - Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/d69249dex991.htm)) |
| August 12, 2026 | [TALPHERA, INC. earnings report](https://sec-api.dev/companies/tlph/catalysts) | TLPH |  | completed | "Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427925/000143774926027311/ex_1003190.htm)) |
| August 12, 2026 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "N.C., August 12, 2026 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465926094411/tm2622888d1_ex99-1.htm)) |
| August 12, 2026 | [Connect Biopharma Holdings Ltd earnings report](https://sec-api.dev/companies/cntb/catalysts) | CNTB |  | completed | "Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000027/cntbq22026earningsrelease.htm)) |
| August 12, 2026 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/aeon-20260812xex99d1.htm)) |
| August 12, 2026 | [Longeveron Inc. earnings report](https://sec-api.dev/companies/lgvn/catalysts) | LGVN |  | completed | "Announces 2026 Second Quarter Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1721484/000121390026088365/ea030175701ex99-1.htm)) |
| August 12, 2026 | [Kailera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klra/catalysts) | KLRA |  | completed | "Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-ex99_1.htm)) |
| August 12, 2026 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, August 12, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/plx-20260812xex99d1.htm)) |
| August 12, 2026 | [STRO-004 earnings report](https://sec-api.dev/pdufa/stro-004) | STRO |  | completed | "Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312526345733/stro-ex99_1.htm)) |
| August 12, 2026 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm)) |
| August 12, 2026 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - August 12, 2026 — Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended June 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000039/aztrpressrelease6302026-ex.htm)) |
| August 12, 2026 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-63026x8kex991.htm)) |
| August 12, 2026 | [Humacyte, Inc. earnings report](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed | "Announces Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000110465926094440/tm2622949d1_ex99-1.htm)) |
| August 12, 2026 | [CYPHERPUNK TECHNOLOGIES INC. earnings report](https://sec-api.dev/companies/cyph/catalysts) | CYPH |  | completed | "Mass. - August 12, 2026 - Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509745/000110465926094445/tm2622925d1_ex99-1.htm)) |
| August 12, 2026 | [NEO100 (NEO100) topline data readout](https://sec-api.dev/pdufa/neo100) | NTHI |  | completed, positive | ""Looking ahead, we look forward to presenting topline results from the Phase 2a study of NEO100 in recurrent IDH1-mutant high-grade glioma on August 12, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1979414/000182912626008543/neonctechnologies_ex99-1.htm)) |
| August 12, 2026 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "N.C., August 12, 2026 - Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the second quarter ended June 30, 2026, and provided corporate and regulatory updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465926094466/tm2614433d1_ex99-1.htm)) |
| August 12, 2026 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, August 12, 2026 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced second quarter 2026 financial results and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774926027165/ex_1003235.htm)) |
| August 12, 2026 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774926027313/ex_966798.htm)) |
| August 12, 2026 | [SP001 FDA approval](https://sec-api.dev/pdufa/sp001) | SPRO |  | completed, approved | "We entered the quarter as a company preparing for an important regulatory milestone and have since then announced the FDA approval of Utebzi; a new Phase 2-ready immunology program with SP001; and financing that positions us to continue executing on our mission to deliver transformative therapies to patients," said Esther Rajavelu, President and Chief Executive Officer of Spero." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/d69249dex991.htm)) |
| August 12, 2026 | [Annexon, Inc. earnings report](https://sec-api.dev/companies/annx/catalysts) | ANNX |  | completed | "Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526345672/d119960dex991.htm)) |
| August 12, 2026 | [TScan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tcrx/catalysts) | TCRX |  | completed | "TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783328/000119312526345732/tcrx-ex99_1.htm)) |
| August 12, 2026 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports SECOND Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312526346856/kura-ex99_1.htm)) |
| August 12, 2026 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465926094896/armp-20260812xex99d1.htm)) |
| August 12, 2026 | [Allogene Therapeutics, Inc. earnings report](https://sec-api.dev/companies/allo/catalysts) | ALLO |  | completed | "Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737287/000162828026056198/allo-20260630xexx991q226.htm)) |
| August 12, 2026 | [First Tracks Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/trax/catalysts) | TRAX |  | completed | "First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2091349/000119312526346908/trax-ex99_1.htm)) |
| August 12, 2026 | [Century Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ipsc/catalysts) | IPSC |  | completed | "Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including T1D, and cancer, today reported financial results for the second quarter ended June 30, 2026, and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/tm2622911d1_ex99-1.htm)) |
| August 12, 2026 | [Avalyn Pharma Inc. earnings report](https://sec-api.dev/companies/avln/catalysts) | AVLN |  | completed | "Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/ck0001540171-ex99_1.htm)) |
| August 12, 2026 | [Xilio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/xlo/catalysts) | XLO |  | completed | "Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/xlo-ex99_1.htm)) |
| August 12, 2026 | [SPRUCE BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/sprb/catalysts) | SPRB |  | completed | "Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1683553/000119312526345874/sprb-ex99_1.htm)) |
| August 12, 2026 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/lxeo-ex99_1.htm)) |
| August 12, 2026 | [TSC-101 trial start](https://sec-api.dev/pdufa/tsc-101) | TCRX | with heme malignancies undergoing allogeneic hematopoietic cell transplantation | completed | "In July, the Company announced that it has dosed the first patient in the ongoing Phase 3 ALLOHA-2 clinical trial evaluating TSC-101 for the treatment of patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (allo-HCT)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783328/000119312526345732/tcrx-ex99_1.htm)) |
| August 12, 2026 | [Aprea Therapeutics, Inc. earnings report](https://sec-api.dev/companies/apre/catalysts) | APRE |  | completed | "Aprea Therapeutics Announces Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781983/000110465926094542/apre-20260812xex99d1.htm)) |
| August 12, 2026 | [Acrivon Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrv/catalysts) | ACRV |  | completed | "Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/acrv-ex99_1.htm)) |
| August 12, 2026 | [BioStem Technologies, Inc. earnings report](https://sec-api.dev/companies/bsem/catalysts) | BSEM |  | completed | "BioStem Technologies Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658678/000119312526347211/bsem-ex99_1.htm)) |
| August 12, 2026 | [DYADIC INTERNATIONAL INC earnings report](https://sec-api.dev/companies/dyai/catalysts) | DYAI |  | completed | "ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213809/000149315226037257/ex99-1.htm)) |
| August 12, 2026 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774926027356/ex_1003442.htm)) |
| August 12, 2026 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000022/exhibit991-earningsrelease.htm)) |
| August 12, 2026 | [BIO-TECHNE Corp earnings report](https://sec-api.dev/companies/tech/catalysts) | TECH |  | completed | "Minneapolis/August 12, 2026/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/tech-20260812xex99d1.htm)) |
| August 12, 2026 | [Altimmune, Inc. earnings report](https://sec-api.dev/companies/alt/catalysts) | ALT |  | completed | "Altimmune Announces Second Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/alt-20260812xex99d1.htm)) |
| August 12, 2026 | [BioCardia, Inc. earnings report](https://sec-api.dev/companies/bcda/catalysts) | BCDA |  | completed | "BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/925741/000143774926027332/ex_1003417.htm)) |
| August 12, 2026 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/tm2622742d1_ex99-1.htm)) |
| August 12, 2026 | [Iv tulisokibart primary completion](https://sec-api.dev/pdufa/iv-tulisokibart) | MRK | Ulcerative Colitis | completed | "NCT06052059 (A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06052059)) |
| August 12, 2026 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Plaque Psoriasis | completed | "NCT06088199 (A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06088199)) |
| August 12, 2026 | [ARGX-119 primary completion](https://sec-api.dev/pdufa/argx-119) | ARGX | Amyotrophic Lateral Sclerosis | withdrawn | "NCT06441682 (A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06441682)) |
| August 12, 2026 | [Barzolvolimab primary completion](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Chronic Spontaneous Urticaria | completed | "NCT06445023 (A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06445023)) |
| August 12, 2026 | [Joenja® (leniolisib) primary completion](https://sec-api.dev/pdufa/leniolisib) | PHAR | Common Variable Immunodeficiency (CVID) | completed | "NCT06897358 (Leniolisib for Immune Dysregulation in CVID): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897358)) |
| August 12, 2026 | [Vafseo® (vadadustat) primary completion](https://sec-api.dev/pdufa/vadadustat) | AKBA | Anemia of Chronic Kidney Disease | completed | "NCT06901505 (To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Akebia Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06901505)) |
| August 13, 2026 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312526349170/eldn-ex99_1.htm)) |
| August 13, 2026 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312526347984/fate-ex99_1.htm)) |
| August 13, 2026 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-ex99_1.htm)) |
| August 13, 2026 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465926095931/fbio-20260813xex99d1.htm)) |
| August 13, 2026 | [ROCKWELL MEDICAL, INC. earnings report](https://sec-api.dev/companies/rmti/catalysts) | RMTI |  | completed | "Rockwell Medical Announces Second Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1041024/000162828026056454/a2026q2-26xearningsxpr.htm)) |
| August 13, 2026 | [Cabaletta Bio, Inc. earnings report](https://sec-api.dev/companies/caba/catalysts) | CABA |  | completed | "Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759138/000175913826000038/caba-ex99_1.htm)) |
| August 13, 2026 | [Calidi Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/cldi/catalysts) | CLDI |  | completed | "Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855485/000149315226037840/ex99-1.htm)) |
| August 13, 2026 | [Instil Bio, Inc. earnings report](https://sec-api.dev/companies/til/catalysts) | TIL |  | completed | "Instil Bio Reports Second Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789769/000178976926000055/q2-26er.htm)) |
| August 13, 2026 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000054/crmd_q22026earningspr.htm)) |
| August 13, 2026 | [Pulmatrix, Inc. earnings report](https://sec-api.dev/companies/pulm/catalysts) | PULM |  | completed | "Announces Second Quarter 2026 Financial Results and Progress on Merger" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1574235/000149315226037592/ex99-1.htm)) |
| August 13, 2026 | [Ensysce Biosciences, Inc. earnings report](https://sec-api.dev/companies/ensc/catalysts) | ENSC |  | completed | "Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1716947/000149315226037794/ex99-1.htm)) |
| August 13, 2026 | [ELUTIA INC. earnings report](https://sec-api.dev/companies/elut/catalysts) | ELUT |  | completed | "Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708527/000110465926095934/elut-20260813xex99d1.htm)) |
| August 13, 2026 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/ex_974033.htm)) |
| August 13, 2026 | [Pyxis Oncology, Inc. earnings report](https://sec-api.dev/companies/pyxs/catalysts) | PYXS |  | completed | "Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782223/000119312526347911/pyxs-ex99_1.htm)) |
| August 13, 2026 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/ex99-1.htm)) |
| August 13, 2026 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Second Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm)) |
| August 13, 2026 | [MapLight Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mplt/catalysts) | MPLT |  | completed | "NEWSWIRE) — MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/d48818dex991.htm)) |
| August 13, 2026 | [MiNK Therapeutics, Inc. earnings report](https://sec-api.dev/companies/inkt/catalysts) | INKT |  | completed | "MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840229/000119312526347907/inkt-ex99_1.htm)) |
| August 13, 2026 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/rani-ex99_1.htm)) |
| August 13, 2026 | [Tempest Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tpst/catalysts) | TPST |  | completed | "Tempest Reports Second Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1544227/000119312526349374/tpst-ex99_1.htm)) |
| August 13, 2026 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports Second Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465926095460/tm2623056d1_ex99-1.htm)) |
| August 13, 2026 | [AKTX-101 earnings report](https://sec-api.dev/pdufa/aktx-101) | AKTX |  | completed | "Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1541157/000149315226037736/ex99-1.htm)) |
| August 13, 2026 | [Atrium Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rna/catalysts) | RNA |  | completed | "Atrium Therapeutics Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2093101/000119312526349482/d149126dex991.htm)) |
| August 13, 2026 | [PDS Biotechnology Corp earnings report](https://sec-api.dev/companies/pdsb/catalysts) | PDSB |  | completed | "PDS Biotech Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472091/000114036126032650/ef20080122_ex99-1.htm)) |
| August 13, 2026 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465926095905/pmn-20260813xex99d1.htm)) |
| August 13, 2026 | [RT-114 trial start](https://sec-api.dev/pdufa/rt-114) | RANI |  | completed | "Rani also announced today that the first participants have been dosed in the Phase 1a study expansion cohort of RT-114, an orally administered RaniPill Capsule delivering PG-102, a" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/rani-ex99_1.htm)) |
| August 13, 2026 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces First Quarter 2027 Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126032644/ef20079525_ex99-1.htm)) |
| August 13, 2026 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813xex99d1.htm)) |
| August 13, 2026 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS SECOND QUARTER 2026 RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390026089137/ea030192901ex99-1.htm)) |
| August 13, 2026 | [Eikon Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eikn/catalysts) | EIKN |  | completed | "Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1861123/000119312526349154/eikn-ex99_1.htm)) |
| August 13, 2026 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526349182/eq-ex99_1.htm)) |
| August 13, 2026 | [4D Molecular Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fdmt/catalysts) | FDMT |  | completed | "4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm)) |
| August 13, 2026 | [Serina Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ser/catalysts) | SER |  | completed | "Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000048/ser-20260813xex991_earning.htm)) |
| August 13, 2026 | [MeiraGTx Holdings plc earnings report](https://sec-api.dev/companies/mgtx/catalysts) | MGTX |  | completed | "LONDON and NEW YORK, August 13, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the second quarter ended June 30, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1735438/000110465926095491/mgtx-20260813xex99d1.htm)) |
| August 13, 2026 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526349127/spry-ex99_1.htm)) |
| August 13, 2026 | [Kodiak Sciences Inc. earnings report](https://sec-api.dev/companies/kod/catalysts) | KOD |  | completed | "Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-ex99_1.htm)) |
| August 13, 2026 | [Edesa Biotech, Inc. earnings report](https://sec-api.dev/companies/edsa/catalysts) | EDSA |  | completed | "Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1540159/000117184326005499/exh_991.htm)) |
| August 13, 2026 | [Cingulate Inc. earnings report](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed | "Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226037605/ex99-1.htm)) |
| August 13, 2026 | [Karyopharm Therapeutics Inc. earnings report](https://sec-api.dev/companies/kpti/catalysts) | KPTI |  | completed | "Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/kpti-ex99_1.htm)) |
| August 13, 2026 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm)) |
| August 13, 2026 | [Aktis Oncology, Inc. earnings report](https://sec-api.dev/companies/akts/catalysts) | AKTS |  | completed | "Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/ck0002035832-ex99_1.htm)) |
| August 13, 2026 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000095010326012287/dp251718_ex9901.htm)) |
| August 13, 2026 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000073/goss-20260813xexx991xearni.htm)) |
| August 13, 2026 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/crbu-20260813xexx991.htm)) |
| August 13, 2026 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315226037575/ex99-1.htm)) |
| August 13, 2026 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-ex99_1.htm)) |
| August 13, 2026 | [ELI-002 trial start](https://sec-api.dev/pdufa/eli-002) | ELTX |  | completed | "Announced the activation of an investigator-initiated Phase 1 neoadjuvant trial evaluating ELI-002 7P plus chemotherapy and an anti-PD-1 checkpoint inhibitor in borderline resectable and resectable pancreatic ductal adenocarcinoma ("PDAC")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx2q26pr.htm)) |
| August 13, 2026 | [Camp4 Therapeutics Corp earnings report](https://sec-api.dev/companies/camp/catalysts) | CAMP |  | completed | "CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736730/000162828026056758/camp4reportssecondquarter2.htm)) |
| August 13, 2026 | [Cadrenal Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cvkd/catalysts) | CVKD |  | completed | "Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937993/000121390026089147/ea030204201ex99-1.htm)) |
| August 13, 2026 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/kynb-ex99_1.htm)) |
| August 13, 2026 | [Dogwood Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dwtx/catalysts) | DWTX |  | completed | "Dogwood Therapeutics Announces Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818844/000110465926095512/dwtx-20260813xex99d1.htm)) |
| August 13, 2026 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx2q26pr.htm)) |
| August 13, 2026 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Announces Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000112/pths-pressreleasex20260813.htm)) |
| August 13, 2026 | [Parabilis Medicines, Inc. earnings report](https://sec-api.dev/companies/pbls/catalysts) | PBLS |  | completed | "Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1657677/000119312526347869/ck0001657677-ex99_1.htm)) |
| August 13, 2026 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/exhibit99-1earningspressre.htm)) |
| August 13, 2026 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026 and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000149315226037787/ex99-1.htm)) |
| August 13, 2026 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226037610/ex99-1.htm)) |
| August 13, 2026 | [Zenbexus (iberdomide hydrochloride) FDA approval](https://sec-api.dev/pdufa/iberdomide) | BMY |  | completed, approved | "Zenbexus \| iberdomide \| 8/13/2026 \| To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| August 13, 2026 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Crohn's Disease (CD) | completed | "NCT02782663 (A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-18 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02782663?tab=results)) |
| August 13, 2026 | [Imvt-1401 (batoclimab) topline data readout](https://sec-api.dev/pdufa/imvt-1401-batoclimab) | IMVT | Graves Disease | completed | "NCT05907668 (A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05907668?tab=results)) |
| August 13, 2026 | [Lumvoa™ (veligrotug) topline data readout](https://sec-api.dev/pdufa/veligrotug) | VRDN | Thyroid Eye Disease | completed | "NCT06384547 (A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-01 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06384547?tab=results)) |
| August 13, 2026 | [Lysergide tartrate primary completion](https://sec-api.dev/pdufa/lysergide) | DFTX | Generalized Anxiety Disorder | completed | "NCT06809595 (A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-13 (ACTUAL); Lead Sponsor Definium Therapeutics US, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06809595)) |
| August 14, 2026 | [Jasper Therapeutics, Inc. earnings report](https://sec-api.dev/companies/jspr/catalysts) | JSPR |  | completed | "NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper"), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended June 30, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1788028/000121390026090055/ea030204901ex99-1.htm)) |
| August 14, 2026 | [BeyondSpring Inc. earnings report](https://sec-api.dev/companies/bysi/catalysts) | BYSI |  | completed | "BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677940/000117184326005557/exh_991.htm)) |
| August 14, 2026 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "N.J., August 14, 2026 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today reported financial results for the third quarter of fiscal year 2026, ended June 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_ex99-1.htm)) |
| August 14, 2026 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/cue-ex99_1.htm)) |
| August 14, 2026 | [Traws Pharma, Inc. earnings report](https://sec-api.dev/companies/traw/catalysts) | TRAW |  | completed | "Reports Q2 2026 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1130598/000110465926097226/tm2623190d1_ex99-1.htm)) |
| August 14, 2026 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312526352208/lona-ex99_1.htm)) |
| August 14, 2026 | [Biologics earnings report](https://sec-api.dev/pdufa/biologics) | HCWB |  | completed | "FL - August 14, 2026 - HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and six months ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828673/000149315226038258/ex99-1.htm)) |
| August 14, 2026 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390026090182/ea030222601ex99-1.htm)) |
| August 14, 2026 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/ex_967804.htm)) |
| August 14, 2026 | [Lantern Pharma Inc. earnings report](https://sec-api.dev/companies/ltrn/catalysts) | LTRN |  | completed | "Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1763950/000149315226037979/ex99-1.htm)) |
| August 14, 2026 | [Moleculin Biotech, Inc. earnings report](https://sec-api.dev/companies/mbrx/catalysts) | MBRX |  | completed | "Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1659617/000143774926027835/ex_1004839.htm)) |
| August 14, 2026 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465926097180/tm2623188d1_ex99-1.htm)) |
| August 14, 2026 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390026090181/ea030222701ex99-1.htm)) |
| August 14, 2026 | [Stenoparib earnings report](https://sec-api.dev/pdufa/stenoparib) | ALLR |  | completed | "- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1860657/000121390026090183/ea030215701ex99-1.htm)) |
| August 14, 2026 | [Aptevo Therapeutics Inc. earnings report](https://sec-api.dev/companies/apvo/catalysts) | APVO |  | completed | "Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000119312526350537/apvo-ex99_1.htm)) |
| August 14, 2026 | [Scienture Holdings, Inc. earnings report](https://sec-api.dev/companies/scnx/catalysts) | SCNX |  | completed | "NY, Aug. 14, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three and six months ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382574/000149315226039474/ex99-1.htm)) |
| August 14, 2026 | [Neumora Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nmra/catalysts) | NMRA |  | completed | "Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1885522/000119312526350349/nmra-ex99_1.htm)) |
| August 14, 2026 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "2026 - Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its &filig;nancial and operating results for the second quarter ended June 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926096417/tm2623143d1_ex99-1.htm)) |
| August 14, 2026 | [Enveric Biosciences, Inc. earnings report](https://sec-api.dev/companies/envb/catalysts) | ENVB |  | completed | "Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/890821/000149315226038385/ex99-1.htm)) |
| August 14, 2026 | [Vistagen Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vtgn/catalysts) | VTGN |  | completed | "Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1411685/000162828026056953/vtgn-20260814xex991.htm)) |
| August 14, 2026 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036126032946/ef20080011_ex99-1.htm)) |
| August 14, 2026 | [Quoin Pharmaceuticals Ltd. earnings report](https://sec-api.dev/companies/qnrx/catalysts) | QNRX |  | completed | "Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465926097094/tm2623115d1_ex99-1.htm)) |
| August 14, 2026 | [Buntanetap earnings report](https://sec-api.dev/pdufa/buntanetap) | ANVS |  | completed | "ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/tm2623272d1_ex99-1.htm)) |
| August 14, 2026 | [Sodium Bicarbonate (sodium bicarbonate) FDA approval](https://sec-api.dev/pdufa/bicarbonate) | BAX |  | completed, approved | "NDA218524 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260814, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product SODIUM BICARBONATE (SODIUM BICARBONATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218524%22)) |
| August 14, 2026 | [Replimune Group, Inc. earnings report](https://sec-api.dev/companies/repl/catalysts) | REPL |  | completed | "Reports Fiscal First Quarter 2027 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926096483/tm2623208d1_ex99-1.htm)) |
| August 14, 2026 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/pmvp-ex99_1.htm)) |
| August 14, 2026 | [Silexion Therapeutics Corp earnings report](https://sec-api.dev/companies/slxn/catalysts) | SLXN |  | completed | "Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022416/000117891326004136/exhibit_99-1.htm)) |
| August 14, 2026 | [IRulya Therapeutics Inc. earnings report](https://sec-api.dev/companies/irla/catalysts) | IRLA |  | completed | "Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662774/000119312526350568/d163839dex991.htm)) |
| August 14, 2026 | [TuHURA Biosciences, Inc./NV earnings report](https://sec-api.dev/companies/hura/catalysts) | HURA |  | completed | "TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498382/000119312526350425/hura-ex99_1.htm)) |
| August 14, 2026 | [LYNPARZA® (olaparib) topline data readout](https://sec-api.dev/pdufa/olaparib) | MRK | Advanced Solid Neoplasms | completed | "NCT03742895 (Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03742895?tab=results)) |
| August 14, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Overweight or Obesity | completed | "NCT05869903 (A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-08-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05869903?tab=results)) |
| August 14, 2026 | [Sonesitatug vedotin primary completion](https://sec-api.dev/pdufa/sonesitatug-vedotin) | AZN | Gastric Cancer; Gastroesophageal Junction Cancer | completed | "NCT07143604 (A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-14 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07143604)) |
| August 15, 2026 | [VYD2311 primary completion](https://sec-api.dev/pdufa/vyd2311) | IVVD | COVID-19 | completed | "NCT07655180 (Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-15 (ACTUAL); Lead Sponsor Invivyd, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07655180)) |
| August 17, 2026 | [Azora Therapeutics, Inc. (DE) earnings report](https://sec-api.dev/companies/azr/catalysts) | AZR |  | completed | "Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company") today provided a business update and reported its financial results for the 2026 second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1513525/000121390026090482/ea030196601ex99-1.htm)) |
| August 17, 2026 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA assigned a Prescription Drug User Fee Act date of August 17, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000008/a2026q1ex991.htm)) |
| August 17, 2026 | [Cisplatin PDUFA date](https://sec-api.dev/pdufa/cisplatin) | MRK |  | scheduled | "§ FDA set PDUFA date of Aug. 17, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm)) |
| August 17, 2026 | [Cisplatin PDUFA date](https://sec-api.dev/pdufa/cisplatin) | PFE |  | scheduled | "The FDA has set a PDUFA target action date of August 17, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-3292026xex99.htm)) |
| August 17, 2026 | [NRX Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/nrxp/catalysts) | NRXP |  | completed | "NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719406/000143774926028111/ex_1005774.htm)) |
| August 17, 2026 | [Vyvgart (efgartigimod alfa) topline data readout](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX | autoimmune myositis | completed, positive | "Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926097589/tm2623372d1_ex99-1.htm)) |
| August 17, 2026 | [Eluxadoline primary completion](https://sec-api.dev/pdufa/eluxadoline) | ABBV | Irritable Bowel Syndrome | completed | "NCT03339128 (Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03339128)) |
| August 17, 2026 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Metastatic Non-small Cell Lung Cancer | completed | "NCT05984277 (A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05984277)) |
| August 17, 2026 | [Navacaprant primary completion](https://sec-api.dev/pdufa/navacaprant) | NMRA | Major Depressive Disorder | withdrawn | "NCT06029439 (Study to Assess the Safety and Effectiveness of NMRA-335140-501): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor Neumora Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06029439)) |
| August 18, 2026 | [Avexitide topline data readout](https://sec-api.dev/pdufa/avexitide) | AMLX |  | completed, positive | "On August 18, 2026, the Company announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 ("GLP-1") receptor antagonist, in participants with post-bariatric hypoglycemia ("PBH") following Roux-en-Y gastric bypass ("RYGB") surgery." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1658551/000119312526354716/d180533d8k.htm)) |
| August 18, 2026 | [Edurant Ped (rilpivirine hydrochloride) primary completion](https://sec-api.dev/pdufa/rilpivirine) | JNJ | Human Immunodeficiency Virus Type 1 | completed | "NCT02494986 (A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-18 (ACTUAL); Lead Sponsor Janssen Sciences Ireland UC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02494986)) |
| August 18, 2026 | [Fludarabine topline data readout](https://sec-api.dev/pdufa/fludarabine) | GILD | Relapsed/Refractory Mantle Cell Lymphoma | completed | "NCT04880434 (Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04880434?tab=results)) |
| August 18, 2026 | [MRNA-1345 topline data readout](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06097299 (A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097299?tab=results)) |
| August 18, 2026 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Platinum-resistant Ovarian Cancer | completed | "NCT06619236 (Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-18 (ACTUAL); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619236)) |
| August 2026 | [Raludotatug deruxtecan (r-dxd) primary completion](https://sec-api.dev/pdufa/raludotatug-deruxtecan-r-dxd) | MRK | Gastrointestinal Cancer | delayed | "NCT06864169 (A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06864169)) |
| August 19, 2026 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "/ Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today reported its consolidated second-quarter 2026 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000119312526356915/d380271dex991.htm)) |
| August 19, 2026 | [Pasatru (garetosmab-grts) FDA approval](https://sec-api.dev/pdufa/garetosmab-grts) | REGN |  | completed, approved | "Pasatru \| garetosmab-grts \| 8/19/2026 \| To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| August 19, 2026 | [Iptacopan (lnp023) primary completion](https://sec-api.dev/pdufa/iptacopan-lnp023) | NVS | Age-Related Macular Degeneration | completed | "NCT05230537 (A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05230537)) |
| August 19, 2026 | [EDP-938 topline data readout](https://sec-api.dev/pdufa/edp-938) | ENTA | RSV Infection | completed | "NCT05568706 (A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Enanta Pharmaceuticals, Inc; Results First Posted 2026-08-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05568706?tab=results)) |
| August 19, 2026 | [Cab la + rpv la primary completion](https://sec-api.dev/pdufa/cab-la-rpv-la) | GSK | HIV Infections | completed | "NCT06694805 (A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-19 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06694805)) |
| August 20, 2026 | [XPHOZAH® (tenapanor) primary completion](https://sec-api.dev/pdufa/tenapanor) | ARDX | Irritable Bowel Syndrome With Constipation (IBS-C) | completed | "NCT05643534 (Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-20 (ACTUAL); Lead Sponsor Ardelyx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05643534)) |
| August 20, 2026 | [Patidegib topical gel primary completion](https://sec-api.dev/pdufa/patidegib-topical-gel) | SLGL | Gorlin Syndrome | completed | "NCT06050122 (Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-20 (ACTUAL); Lead Sponsor Sol-Gel Technologies, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06050122)) |
| August 21, 2026 | [Bf-200 ala and red light led lamp topline data readout](https://sec-api.dev/pdufa/bf-200-ala-and-red-light-led-lamp) | BFRI | Actinic Keratoses | completed | "NCT05662202 (Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-03 (ACTUAL); Lead Sponsor Biofrontera Inc.; Results First Posted 2026-08-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05662202?tab=results)) |
| August 21, 2026 | [ABBV-444 primary completion](https://sec-api.dev/pdufa/abbv-444) | ABBV | Dry Eye Disease | completed | "NCT07284381 (A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-21 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284381)) |
| August 22, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | scheduled | "--Deramiocel BLA Remains Under Active FDA Review, with PDUFA Target Action Date of August 22, 2026--" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/capr-20260729xex99d1.htm)) |
| August 23, 2026 | [Pariglasgene brecaparvovec PDUFA date](https://sec-api.dev/pdufa/pariglasgene-brecaparvovec) | RARE | glycogen storage disease type Ia | scheduled | "The FDA granted the BLA Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526062568/rare-20260223.htm)) |
| August 24, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | delayed | "Press Release, titled "Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA", dated August 24, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824x8k.htm)) |
| August 24, 2026 | [PRECISION BIOSCIENCES INC trial start](https://sec-api.dev/companies/dtil/catalysts) | DTIL | Duchenne muscular dystrophy | completed | "On August 24, 2026, Precision BioSciences, Inc. (the "Company") issued a press release announcing the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy ("DMD") at Arkansas Children's Hospital." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1357874/000162828026058512/dtil-20260824.htm)) |
| August 2026 | [Voydeya (danicopan) primary completion](https://sec-api.dev/pdufa/danicopan) | AZN | Paroxysmal Nocturnal Hemoglobinuria | delayed | "NCT05389449 (A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05389449)) |
| August 2026 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Resectable Non-small Cell Lung Cancer | delayed | "NCT06161441 (A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06161441)) |
| August 24, 2026 | [Flu mrna (formulation b1) primary completion](https://sec-api.dev/pdufa/flu-mrna-formulation-b1) | GSK | Influenza, Human | completed | "NCT07204964 (A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-24 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204964)) |
| August 24, 2026 | [Imaavy (nipocalimab-aahu) label expansion decision](https://sec-api.dev/pdufa/nipocalimab-aahu) | JNJ |  | completed, approved | "BLA761430 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20260824, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product IMAAVY (NIPOCALIMAB-AAHU)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761430%22)) |
| August 25, 2026 | [Vyome Holdings, Inc earnings report](https://sec-api.dev/companies/hind/catalysts) | HIND |  | completed | "25, 2026 — Vyome Holdings, Inc. ("Vyome"), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427570/000121390026093512/ea030322801ex99-1.htm)) |
| August 25, 2026 | [Ziihera® (zanidatamab) PDUFA date](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | with first-line | completed, approved | "•U.S. Food and Drug Administration (FDA) granted Priority Review and set Prescription Drug User Fee Act (PDUFA) target action date of August 25, 2026 for supplemental Biologics License Application (sBLA) for zanidatamab containing combinations in first-line (1L) gastroesophageal adenocarcinoma (GEA)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)) |
| August 25, 2026 | [Ivonescimab topline data readout](https://sec-api.dev/pdufa/ivonescimab) | SMMT | advanced biliary tract cancer | completed, positive | "On August 25, 2026, Summit Therapeutics Inc. issued a press release noting that its partner, Akeso, Inc., ("Akeso") announced positive topline results from the randomized Phase III HARMONi-GI1 study ("HARMONi-GI1") evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000074/smmt-20260825.htm)) |
| August 25, 2026 | [Royalty Pharma plc PDUFA date](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | scheduled | "The FDA has set a Prescription Drug User Fee Act target action date of August 25, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm)) |
| August 25, 2026 | [Jazz Pharmaceuticals plc PDUFA date](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | scheduled | "Our sBLA based on these results is currently under Priority Review with FDA and has a PDUFA date of August 25, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm)) |
| August 25, 2026 | [ANAVEX LIFE SCIENCES CORP. earnings report](https://sec-api.dev/companies/avxl/catalysts) | AVXL |  | completed | "Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001143/e7897_ex99-1.htm)) |
| August 25, 2026 | [TEVIMBRA® (tislelizumab) label expansion decision](https://sec-api.dev/pdufa/tislelizumab) | ONC |  | completed, approved | "On August 25, 2026, we announced that the U.S. Food and Drug Administration ("FDA") approved the supplemental Biologics License Application ("sBLA") for TEVIMBRA in combination with ZIIHERA and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2+ gastric, gastroesophageal junction, or GEA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000162828026070477/bgne-20260930.htm)) |
| August 25, 2026 | [Tivicay (dolutegravir sodium) label expansion decision](https://sec-api.dev/pdufa/dolutegravir) | GSK |  | completed, approved | "NDA204790 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20260825, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TIVICAY (DOLUTEGRAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204790%22)) |
| August 25, 2026 | [Ziihera® (zanidatamab) FDA approval](https://sec-api.dev/pdufa/zanidatamab) | JAZZ |  | completed, approved | "DUBLIN, August 25, 2026 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/exhibit991pr.htm)) |
| August 25, 2026 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide trial start](https://sec-api.dev/pdufa/ihl-42x) | IXHL |  | completed | "Incannex Announces First Patient Dosed in DReAMzz" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873875/000121390026093244/ea030314001ex99-1.htm)) |
| August 25, 2026 | [Daxdilimab topline data readout](https://sec-api.dev/pdufa/daxdilimab) | AMGN | Idiopathic Inflammatory Myositis | completed | "NCT05669014 (A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-02 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-08-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669014?tab=results)) |
| August 25, 2026 | [Combination treatment of pds0101 and pembrolizumab primary completion](https://sec-api.dev/pdufa/combination-treatment-of-pds0101-and-pembrolizumab) | PDSB |  | withdrawn | "NCT06790966 (Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-08-25 (ACTUAL); Lead Sponsor PDS Biotechnology Corp.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06790966)) |
| August 25, 2026 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | Respiratory Syncytial Virus (RSV) | completed | "NCT07543380 (A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-25 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07543380)) |
| August 25, 2026 | [Tevimbra (tislelizumab-jsgr) label expansion decision](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC |  | completed, approved | "BLA761232 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260825, review_priority PRIORITY; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22)) |
| August 26, 2026 | [PHIBRO ANIMAL HEALTH CORP earnings report](https://sec-api.dev/companies/pahc/catalysts) | PAHC |  | completed | "TEANECK, N.J., August 26, 2026 (Business Wire) - Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069899/000110465926101531/pahc-20260826xex99d1.htm)) |
| August 26, 2026 | [Betabart trial start](https://sec-api.dev/pdufa/betabart) | RADX | B7-H3 expressing tumors | completed | "Sydney, Australia - 26 August 2026 - Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) in patients with B7-H3 expressing tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1949257/000121390026093730/ea030344701ex99-1.htm)) |
| August 26, 2026 | [RASONQUE (daraxonrasib) FDA approval](https://sec-api.dev/pdufa/daraxonrasib) | RVMD | To treat metastatic pancreatic cancer | completed, approved | "Rasonque \| daraxonrasib \| 8/26/2026 \| To treat metastatic pancreatic cancer" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| August 26, 2026 | [RHUPH20 topline data readout](https://sec-api.dev/pdufa/rhuph20) | BMY | Melanoma | completed | "NCT05625399 (A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-04 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05625399?tab=results)) |
| August 26, 2026 | [Elrexfio (elranatamab) primary completion](https://sec-api.dev/pdufa/elranatamab) | PFE | Multiple Myeloma | completed | "NCT06152575 (MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-08-26 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06152575)) |
| August 26, 2026 | [Dusquetide topline data readout](https://sec-api.dev/pdufa/dusquetide) | SNGX | Behçet Disease | completed | "NCT06386744 (Dusquetide for the Treatment of Behcet's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-23 (ACTUAL); Lead Sponsor Soligenix; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06386744?tab=results)) |
| August 26, 2026 | [Zepbound (tirzepatide) label expansion decision](https://sec-api.dev/pdufa/tirzepatide) | LLY |  | completed, approved | "NDA217806 SUPPL-41 (Efficacy): submission_status AP, submission_status_date 20260826, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product ZEPBOUND (TIRZEPATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217806%22)) |
| August 27, 2026 | [LISRAYA™ (brepocitinib) FDA approval](https://sec-api.dev/pdufa/brepocitinib) | ROIV | Dermatomyositis | completed, approved | "On August 27, 2026, Roivant Sciences Ltd. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration had approved the New Drug" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1635088/000114036126034735/ef20081229_8k.htm)) |
| August 27, 2026 | [Canvuparatide trial start](https://sec-api.dev/pdufa/canvuparatide) | MBX | Hypoparathyroidism | completed | "CARMEL, Ind., and BURLINGTON, Mass., August 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000119312526369674/mbx-ex99_1.htm)) |
| August 27, 2026 | [COMIRNATY (comirnaty) label expansion decision](https://sec-api.dev/pdufa/comirnaty) | BNTX |  | completed, approved | "NEW YORK and MAINZ, GERMANY, August 27, 2026 — Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies' 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.1" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000059/a991bntx_covid-19xfgvarian.htm)) |
| August 27, 2026 | [Bixlenvo (bictegravir sodium; lenacapavir sodium) FDA approval](https://sec-api.dev/pdufa/bictegravir-lenacapavir) | GILD |  | completed, approved | "NDA221104 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20260827, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product BIXLENVO (BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA221104%22)) |
| August 27, 2026 | [Bixlenvo Sunlenca Starter Pack (Copackaged) (bictegravir sodium, lenacapavir sodium; lenacapavir sodium) FDA approval](https://sec-api.dev/pdufa/bictegravir-lenacapavir-lenacapavir) | GILD |  | completed, approved | "NDA221443 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20260827, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) (BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA221443%22)) |
| August 27, 2026 | [Bictegravir PDUFA date](https://sec-api.dev/pdufa/bictegravir) | GILD |  | scheduled | "•Announced U.S. Food and Drug Administration ("FDA") accepted New Drug Application for bictegravir and lenacapavir ("BIC/LEN") for virologically suppressed people with HIV under priority review, with a Prescription Drug User Fee Act ("PDUFA") target action date of August 27, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm)) |
| August 27, 2026 | [Lifevantage Corp earnings report](https://sec-api.dev/companies/lfvn/catalysts) | LFVN |  | completed | "LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/849146/000119312526371265/lfvn-ex99_1.htm)) |
| August 27, 2026 | [Yeztugo® (lenacapavir) label expansion decision](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed, approved | "NDA215974 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20260827, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product SUNLENCA (LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215974%22)) |
| August 27, 2026 | [NIKTIMVO (axatilimab) primary completion](https://sec-api.dev/pdufa/axatilimab) | SNDX | Idiopathic Pulmonary Fibrosis | completed | "NCT06132256 (MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-27 (ACTUAL); Lead Sponsor Syndax Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132256)) |
| August 27, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Diabetes Mellitus, Type 2 | completed | "NCT06260722 (Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-27 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260722)) |
| August 27, 2026 | [Intervention: as mdi topline data readout](https://sec-api.dev/pdufa/intervention-as-mdi) | AZN | Asthma | completed | "NCT06644924 (A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-08-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06644924?tab=results)) |
| August 28, 2026 | [QYLEKI (QRX003) interim data readout](https://sec-api.dev/pdufa/qrx003) | QNRX | Netherton Syndrome | completed, positive | "August 28, 2026, Quoin reported positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465926123960/tm2629259d1_ex99-1.htm)) |
| August 28, 2026 | [IBio, Inc. earnings report](https://sec-api.dev/companies/ibio/catalysts) | IBIO |  | completed | "Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1420720/000142072026000019/ibio-20260828xex99d1.htm)) |
| August 28, 2026 | [Fruquintinib+sintilimab primary completion](https://sec-api.dev/pdufa/fruquintinib-sintilimab) | HCM | Advanced Renal Cell Carcinoma | completed | "NCT05522231 (Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-08-28 (ACTUAL); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05522231)) |
| August 28, 2026 | [Domvanalimab primary completion](https://sec-api.dev/pdufa/domvanalimab) | RCUS | Advanced Upper Gastrointestinal Tract Adenocarcinoma | completed | "NCT05568095 (A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-28 (ACTUAL); Lead Sponsor Arcus Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05568095)) |
| August 28, 2026 | [Met097 injection topline data readout](https://sec-api.dev/pdufa/met097) | PFE | Obesity; Overweight or Obesity | completed | "NCT06712836 (A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-08-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712836?tab=results)) |
| August 28, 2026 | [MIMRYLO™ (rusfertide) FDA approval](https://sec-api.dev/pdufa/rusfertide) | TAK | To treat erythrocytosis in adults with polycythemia vera | completed, approved | "Mimrylo \| rusfertide \| 8/28/2026 \| To treat erythrocytosis in adults with polycythemia vera" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| August 28, 2026 | [WEZLANA® (ustekinumab) label expansion decision](https://sec-api.dev/pdufa/ustekinumab) | JNJ |  | completed, approved | "BLA761044 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20260828, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product STELARA (USTEKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761044%22)) |
| August 31, 2026 | [Entyvio® (vedolizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/vedolizumab) | ALVO |  | completed | "REYKJAVIK, Iceland, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326005793/exh_991.htm)) |
| August 31, 2026 | [XPOVIO® (selinexor) NDA/BLA submission](https://sec-api.dev/pdufa/selinexor) | KPTI | myelofibrosis | completed | "The Company's primary focus is on marketing XPOVIO in its currently approved indications and on developing and seeking regulatory approval of selinexor for the treatment of myelofibrosis, for which the Company submitted a supplemental New Drug Application to the FDA on August 31, 2026 seeking accelerated approval." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1503802/000119312526444164/d141618dex991.htm)) |
| August 31, 2026 | [GEA-01 topline data readout](https://sec-api.dev/pdufa/gea-01) | ONC |  | completed, positive | "On August 31, 2026, we announced positive topline results from the second interim analysis of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive ("HER2+") locally advanced or metastatic gastroesophageal adenocarcinoma ("GEA")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000162828026070477/bgne-20260930.htm)) |
| August 31, 2026 | [MYQORZO® (aficamten) primary completion](https://sec-api.dev/pdufa/aficamten) | CYTK | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | completed | "NCT06081894 (A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-31 (ACTUAL); Lead Sponsor Cytokinetics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06081894)) |
| August 31, 2026 | [ORZEYFUL (oveporexton) topline data readout](https://sec-api.dev/pdufa/oveporexton) | TAK | Narcolepsy Type 1 | completed | "NCT06470828 (A Study of TAK-861 for the Treatment of Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-08-31." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06470828?tab=results)) |

Other months: https://sec-api.dev/fda-calendar/2026-07 , https://sec-api.dev/fda-calendar/2026-09. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates August 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-08

```bibtex
@misc{secapidev_fda_calendar_2026_08_20261116,
  title        = {PDUFA dates August 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-08}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_08_20261116","title":"PDUFA dates August 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-08","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
